← All trials
NCT05083247
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2021
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2025
- First posted
- Oct 19, 2021
- Last posted
- Oct 19, 2021
- Enrollment
- 174
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Erasmus University RotterdamLead sponsor
- Ghent UniversityCollaborator
- Katholieke Universiteit LeuvenCollaborator
- University of GroningenCollaborator
- Free University of BrusselsCollaborator
- Belgian Group of Digestive OncologyCollaborator
- ChirecCollaborator
- Free University of BrusselsOverall official - principal investigator
- Hospital de JolimontCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.